A5014863618- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Neurogenesis and neuroplasticity mechanisms
- Radiopharmaceutical Chemistry and Applications
- Pluripotent Stem Cells Research
- Microtubule and mitosis dynamics
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Science, Research, and Medicine
- Hedgehog Signaling Pathway Studies
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- RNA Research and Splicing
- Viral Infectious Diseases and Gene Expression in Insects
- MicroRNA in disease regulation
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Bioinformatics and Genomic Networks
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Treatments and Studies
- Computational Drug Discovery Methods
- Cellular Mechanics and Interactions
- Health Systems, Economic Evaluations, Quality of Life
University of Bern
2018-2024
British Columbia Children's Hospital
2013-2021
University of British Columbia
2011-2021
University Hospital of Bern
2021
Weill Cornell Medicine
2016-2018
Cornell University
2016-2018
NewYork–Presbyterian Hospital
2017
Presbyterian Hospital
2017
New York Hospital Queens
2017
German Cancer Research Center
2013
Abstract Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe development a robust precision cancer care platform integrates whole-exome sequencing with living biobank enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures 19 xenograft (PDX) models have been established from 769 patients enrolled in...
// Joanna Triscott 1 , Cathy Lee Kaiji Hu Abbas Fotovati Rachel Berns Mary Pambid Margaret Luk 2 Richard E. Kast 3 Esther Kong 4 Eric Toyota Stephen Yip Brian 5 and Sandra Dunn Department of Pediatrics, University British Columbia, Vancouver, BC Pathology, Vancouver General Hospital, Psychiatry, Vermont, Burlington, VT, USA Pathology & Laboratory Medicine, Centre for Translational Applied Genomics, Cancer Agency, Surgery, Columbia Correspondence: Dunn, email: Keywords : glioblastoma,...
Abstract Medulloblastoma is the most common malignant brain tumor in children. This disease heterogeneous and composed of four subtypes medulloblastoma [WNT, Sonic Hedgehog (SHH), Group 3, 4]. An immediate goal to identify novel molecular targets for aggressive forms medulloblastoma. Polo-like kinase 1 (PLK1) an oncogenic that controls cell cycle proliferation, making it a strong candidate treatment. In this study, pediatric medulloblastomas were subtyped two patient cohorts (discovery...
The Y-box binding protein 1 (YB-1) is upregulated in many human malignancies including glioblastoma (GBM). It also essential for normal brain development, suggesting that YB-1 part of a neural stem cell (NSC) network. Here, we show was highly expressed the subventricular zone (SVZ) mouse fetal tissues but not terminally differentiated primary astrocytes. Conversely, knockout mice had reduced Sox-2, nestin, and musashi-1 expression SVZ. Although murine neurospheres were rich YB-1, its lost...
Glioblastoma multiforme (GBM) ranks among the deadliest types of cancer and given these new therapies are urgently needed. To identify molecular targets, we queried a microarray profiling 467 human GBMs discovered that polo-like kinase 1 (PLK1) was highly expressed in tumors it clustered with proliferative subtype. Patients PLK1-high were more likely to die from their disease suggesting current inactive against such tumors. This prompted us examine its expression brain tumor initiating cells...
Abstract Brain tumors represent the leading cause of childhood cancer mortality, which medulloblastoma (MB) is most frequent malignant tumor. Recent studies have demonstrated presence several MB molecular subgroups, each distinct in terms prognosis and predicted therapeutic response. Groups 1 2 are characterized by relatively good clinical outcomes activation Wnt Shh pathways, respectively. In contrast, groups 3 4 (“non-Shh/Wnt MBs”) distinguished metastatic disease, poor patient outcome,...
Phosphatidylinositol (PI)regulating enzymes are frequently altered in cancer and have become a focus for drug development. Here, we explore the phosphatidylinositol-5-phosphate 4-kinases (PI5P4K), family of lipid kinases that regulate pools intracellular PI, demonstrate PI5P4Kα isoform influences androgen receptor (AR) signaling, which supports prostate (PCa) cell survival. The regulation PI becomes increasingly important setting metabolic stress adaptation PCa during deprivation (AD), as...
Abstract Background Molecular subtyping has allowed for the beginning of personalized treatment in children suffering from medulloblastoma (MB). However, resistance inevitably emerges against these therapies, particularly Sonic Hedgehog (SHH) subtype. We found that with SHH subtype have worst outcome underscoring need to identify new therapeutic targets. Procedure High content screening a 129 compound library identified agents inhibited MB growth. Lead molecular target levels, p90 ribosomal...
The evolutionarily conserved minor spliceosome (MiS) is required for protein expression of ∼714 intron-containing genes (MIGs) crucial cell-cycle regulation, DNA repair, and MAP-kinase signaling. We explored the role MIGs MiS in cancer, taking prostate cancer (PCa) as an exemplar. Both androgen receptor signaling elevated levels U6atac, a small nuclear RNA, regulate activity, which highest advanced metastatic PCa. siU6atac-mediated inhibition PCa vitro model systems resulted aberrant intron...
<div>Abstract<p>Although early prostate cancer depends on the androgen receptor signaling pathway, which is predominant in luminal cells, there much to be understood about contribution of epithelial basal cells progression. Herein, we observe cell type–specific differences importance metabolic enzyme phosphatidylinositol 5-phosphate 4-kinase alpha (PI5P4Kα; gene name <i>PIP4K2A</i>) epithelium. We report development a cell–specific genetically engineered mouse model...
<p>Figure S1. PIP4K2A expression in human scRNA-Seq dataset.</p>
<p>Figure S8. Differentially abundant pathways and metabolites from targeting PIP4K2A.</p>
<p>Figure S6. Prostate morphology resulting from genomic loss of Pip4k2b isoform.</p>
<p>Figure S5. scRNA-Seq comparison with atlas datasets.</p>
<p>Figure S4. Top ten differentially expressed genes in scRNA-Seq clusters.</p>
<p>Figure S2. PI5P4Kα expression enriched in basal compartment.</p>